Rafferty Asset Management LLC Sells 19,185 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Rafferty Asset Management LLC lessened its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 21.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 70,313 shares of the biopharmaceutical company's stock after selling 19,185 shares during the period. Rafferty Asset Management LLC owned 0.12% of Agios Pharmaceuticals worth $2,310,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Venturi Wealth Management LLC bought a new position in Agios Pharmaceuticals in the fourth quarter valued at about $33,000. Wingate Wealth Advisors Inc. acquired a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth about $53,000. Sterling Capital Management LLC raised its position in Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after buying an additional 1,587 shares during the last quarter. KBC Group NV raised its position in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 611 shares during the last quarter. Finally, AlphaQuest LLC raised its position in Agios Pharmaceuticals by 106.2% in the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after buying an additional 2,338 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms have weighed in on AGIO. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price target for the company. Scotiabank dropped their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research note on Friday, May 2nd. Finally, Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of "Hold" and an average target price of $56.00.

Insider Buying and Selling

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares of the company's stock, valued at $3,864,798. This represents a 4.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.30% of the stock is owned by company insiders.

Agios Pharmaceuticals Stock Up 0.7%

Shares of NASDAQ AGIO traded up $0.21 during trading on Friday, reaching $29.80. The company had a trading volume of 440,665 shares, compared to its average volume of 695,398. The company's fifty day moving average price is $28.66 and its 200-day moving average price is $35.92. Agios Pharmaceuticals, Inc. has a 12 month low of $23.42 and a 12 month high of $62.58. The stock has a market cap of $1.73 billion, a P/E ratio of 2.63 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. The company had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, equities analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.